-
SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy
Monday, May 9, 2011 - 8:31am | 50Accuray Incorporated (Nasdaq: ARAY) announced today that the U.S. Securities and Exchange Commission has declared effective the company's Form S-4 Registration Statement relating to the previously announced acquisition of TomoTherapy Incorporated (Nasdaq: TOMO).
-
Oppenheimer Outperform On Medtronic (MDT)
Monday, May 9, 2011 - 8:01am | 154Oppenheimer & Co. has an Outperform rating and a $48 price target on shares of Medtronic (NYSE: MDT), as it previews earnings from Medtronic. In a note to investors, Oppenheimer writes, "MDT's F4Q11 results are due May 24. FY12 guidance will also be provided. We look for accelerated FY12 sales...
-
UK Oft Discloses Veterinary Probe in Statement -Bloomberg (IDXX)
Monday, May 9, 2011 - 7:54am | 23UK Oft discloses a veterinary probe in a statement. Bloomberg cites IDEXX Laboratories (NASDAQ: IDXX).
-
GPRO Continues To Enjoy An Enviable Advantage Amongst New U.S. HPV Entrants, Piper Jaffray Reports
Monday, May 9, 2011 - 7:48am | 77Piper Jaffray continues to believe that Gen-Probe Inc. (NASDAQ: GPRO) enjoys an enviable advantage amongst the new U.S. HPV entrants “with their large installed base of Tigris' that will aid initial account conversions (and believe we have modeled said share shift accordingly).” “That said, we...
-
Goldman Sachs Raises PT, Reiterates CL-Buy On Sirona Dental Systems Following Recent Earnings Release
Monday, May 9, 2011 - 7:38am | 158Sirona Dental Systems (NASDAQ: SIRO) 2QFY11 results came with better-than-expected sales from its two key equipment categories, and increased revenue and operating profit guidance. Results across dental this quarter demonstrate that there is healthy demand for high-tech equipment and that a...
-
Jefferies Raises Forecasts On Sirona Dental Systems
Monday, May 9, 2011 - 7:35am | 112According to Jefferies, Sirona Dental Systems (NASDAQ: SIRO) forecasts are raised. Jefferies said that it is raising its FY11 EPS forecast to $2.90 (from $2.82). “Our price target moves to $57 (from $54) on higher cash flow forecasts. SIRO's fiscal-2Q11 (Mar) adjusted operating income of $47M...
-
J.P. Morgan Maintains Overweight on Gen-Probe (GPRO)
Monday, May 9, 2011 - 7:19am | 117J.P. Morgan is out with its report on Gen-Probe (NASDAQ: GPRO), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Data from Gen-Probe's CLEAR pivotal clinical trial for the company's APTIMA HPV test were presented in a symposium on Sunday evening at the EUROGIN meeting. Results...
-
Steris Corp Reports EPS of $0.61 vs. $0.62 Estimate; Revenues $377.8M vs. $350.28M Estimate
Monday, May 9, 2011 - 7:03am | 22Steris Corp (NYSE: STE) Reports EPS of $0.61 vs. $0.62 Estimate; Revenues $377.8M vs. $350.28M Estimate
-
Market updates: Greece, Chubu Electric, Munich Re, BARC, LLOY, CNA, TCG, ISAT, SRP, ELN, ALKS, VITA, BHP, HBC, LMI
Monday, May 9, 2011 - 6:08am | 1964BHP Billiton Limited (NYSE:BHP) is trading at a price of $95.50, says company and Australia poised to reap benefits of rebalancing of economic weight to Asia; but short to medium-term challenges remain. BHP Billiton Ltd Chairman Jacques Nasser said Monday he believes in a “go-slow” approach to...
-
Top Trade Ideas for the Week of May 9, 2011: The Rest
Sunday, May 8, 2011 - 3:54pm | 126Here are The Rest of the Top 10 for the week: Lear, Ticker:$LEA Lear pulled back after a run higher off of 46.16 support. Finding support at the 50 day Simple Moving Average (SMA) it retested the top near resistance at 52 on Friday. Despite the doji, it has a rising Relative Strength Index (RSI...
-
Abiomed Announces New PROTECT II Data at Society for Cardiovascular Angiography Interventions 2011 Scientific Sessions
Friday, May 6, 2011 - 12:00pm | 89Abiomed, Inc. (NASDAQ: ABMD) today announced results from further 90 day clinical and economic analyses, based on data from the PROTECT II study. The analyses showed a significant reduction of 29% in the Major Adverse Cardiac and Cerebrovascular Event rate for the Impella® arm at 90 days....
-
CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation (CRY)
Friday, May 6, 2011 - 8:52am | 71CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced the final results of its tender offer, including proration results, through its wholly owned subsidiary CL Falcon, Inc., for 49.9 percent of the outstanding shares of...
-
Jefferies Maintains Buy Rating On Orthofix
Friday, May 6, 2011 - 8:39am | 71According to Jefferies, Orthofix Int'l (NASDAQ: OFIX) posted an overall in-line quarter, as weakness in spine stimulation was offset by upside in orthopedics. Jefferies said that the company announced significant progress toward settlement with the spine stimulation DOJ and FCPA investigations,...
-
Jefferies Maintains Hold Rating On Wright Medical Group (WMGI)
Friday, May 6, 2011 - 7:14am | 108According to a recent report from Jefferies, Wright Medical Group (NASDAQ: WMGI) has given very few details on what to expect moving forward causing Jefferies to maintain a hold rating on WMGI. In the report, Jefferies said, "While the company exceeded expectations and offered slightly better...
-
Jefferies Raises PT On Orthofix to $38
Friday, May 6, 2011 - 7:03am | 26Jefferies & Company has raised the price target on Orthofix (NASDAQ: OFIX) from $35 to $38 and maintains its Buy rating.